Related Experiment Video
Updated: May 6, 2026
07:06
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
26.7K
Diffuse gastroduodenitis associated with ulcerative colitis: treatment by infliximab.
Mitsuro Chiba1, Iwao Ono, Hideki Wakamatsu
1Division of Gastroenterology, Nakadori General Hospital.
Summary
This study reports a rare case of diffuse gastroduodenitis in a patient with ulcerative colitis (UC). Infliximab treatment effectively healed the gastroduodenal inflammation and ulceration associated with UC.
Area of Science:
- Gastroenterology
- Immunology
Background:
- Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
- Gastroduodenitis can rarely manifest in UC patients, presenting diagnostic challenges.
- Treatment options for refractory gastroduodenitis in UC are limited.
Observation:
- A 58-year-old male with a history of UC presented with tarry stools.
- Endoscopy revealed diffuse friable mucosa in the duodenum and an ulcerated, narrowed descending portion, with aphthae in the gastric antrum.
- Biopsies confirmed significant inflammatory cell infiltration and cryptitis.
Findings:
- The patient received standard induction therapy with infliximab.
- Following infliximab treatment, the duodenal ulcer healed, forming a scar.
- Mucosal friability resolved, indicating successful treatment of gastroduodenitis.
Implications:
- This case highlights the potential for infliximab to treat rare gastroduodenal manifestations of UC.
- Early diagnosis and appropriate therapy can lead to favorable outcomes in such complex cases.
- Further research may explore infliximab's efficacy in similar gastrointestinal involvements in UC.
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
721
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
721
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
897
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
897
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
780
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
780
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
1.5K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.5K
01:26Inflammatory Bowel Disease I: Introduction
79
Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows...
79
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
61
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal...
61